{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:49:06Z","timestamp":1783532946950,"version":"3.55.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1053\/j.seminhematol.2010.06.005","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T05:04:19Z","timestamp":1285736659000},"page":"335-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Resistance to Imatinib: Mutations and Beyond"],"prefix":"10.1053","volume":"47","author":[{"given":"Paul","family":"La Ros\u00e9e","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.06.005_bib1","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib6","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib7","doi-asserted-by":"crossref","first-page":"353a","DOI":"10.1182\/blood.V114.22.859.859","article-title":"Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients","volume":"114","author":"Mahon","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib8","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib9","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.12186","article-title":"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib","volume":"93","author":"La Rosee","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib11","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib12","first-page":"4244","article-title":"Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases","volume":"62","author":"Wisniewski","year":"2002","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib13","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib14","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1200\/JCO.2009.26.4945","article-title":"Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia","volume":"28","author":"Laneuville","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib15","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib16","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib17","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/leu.2009.193","article-title":"Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history","volume":"24","author":"Jabbour","year":"2010","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib19","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib20","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib22","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nsmb.1486","article-title":"Activation of tyrosine kinases by mutation of the gatekeeper threonine","volume":"15","author":"Azam","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib24","doi-asserted-by":"crossref","first-page":"19466","DOI":"10.1073\/pnas.0609239103","article-title":"Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants","volume":"103","author":"Skaggs","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib25","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib26","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","article-title":"Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib28","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-07-6858","article-title":"BCR\/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations","volume":"68","author":"Stoklosa","year":"2008","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib29","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/leu.2008.78","article-title":"BCR\/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress","volume":"22","author":"Koptyra","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib30","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2008-07-172148","article-title":"BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair","volume":"114","author":"Fernandes","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib31","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells","volume":"103","author":"Chu","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib32","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib33","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","article-title":"Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells","volume":"68","author":"Konig","year":"2008","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib34","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606","volume":"111","author":"Konig","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib35","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2405086","article-title":"Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors","volume":"22","author":"Konig","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib36","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib37","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.thj.6200297","article-title":"No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec\/Glivec)","volume":"4","author":"La Ros\u00e9e","year":"2003","journal-title":"Hematol J"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib40","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/asheducation-2008.1.436","article-title":"Chronic myeloid leukemia stem cells","author":"Jamieson","year":"2008","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib41","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib42","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","article-title":"Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib43","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/1535-7163.MCT-07-2331","article-title":"Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells","volume":"7","author":"Weisberg","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib44","doi-asserted-by":"crossref","first-page":"388a","DOI":"10.1182\/blood.V114.22.941.941","article-title":"Defining extrinsic survival pathways in CML progenitor cells","volume":"114","author":"Mackenzie","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib45","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2008-08-176016","article-title":"Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib","volume":"114","author":"Lemoli","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib47","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1073\/pnas.0900189106","article-title":"Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation","volume":"106","author":"Abrahamsson","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib48","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.emboj.7601485","article-title":"Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation","volume":"26","author":"Coluccia","year":"2007","journal-title":"EMBO J"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib49","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib50","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib52","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib53","first-page":"459","article-title":"In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures","volume":"90","author":"Crossman","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib54","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib56","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib57","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib58","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"Kim","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib59","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.exphem.2009.02.006","article-title":"Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34(+) cells to imatinib","volume":"37","author":"Hatziieremia","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib60","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","article-title":"Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis","volume":"14","author":"Shah","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib62","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1182\/blood-2007-10-113969","article-title":"Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis","volume":"114","author":"Snead","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib63","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/leu.2009.45","article-title":"Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells","volume":"23","author":"Hiwase","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib64","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib65","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib67","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib68","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib69","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib70","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.LBA-1.LBA-1","article-title":"Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the International Randomized Phase III ENESTnd Trial","author":"Saglio","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.005_bib71","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719631000079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719631000079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:48Z","timestamp":1758522048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719631000079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S003719631000079X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance to Imatinib: Mutations and Beyond","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}